Fig. 4

Both early and late blockades of PVRIG inhibit tumor growth in MC38 tumor-bearing mice. a Experimental protocol for murine colon cancer model used in b–e. Mice were injected with PBS, anti-PVRIG mAb or isotype-matched control mAb (rat IgG) intraperitoneally (i.p.) at various time points after injection of 5 × 10⁴ MC38 tumor cells subcutaneously (s.c.) on day 0. b Median tumor size (n = 10 (PBS), n = 8 (rat IgG), n = 12 (anti-PVRIG)) measured at each time point. c Overall survival of mice treated with PBS (n = 33), Rat IgG (n = 31) or anti-PVRIG mAb (n = 38). d Representative photograph and e weight of tumor (n = 8 per group) on day 28 after challenge. f C57BL/6 mice were inoculated subcutaneously (s.c.) with 5 × 10⁴ MC38 colon cancer cells on day 0. Mice were grouped randomly on day 3. And then mice were injected with isotype-matched control mAb (Rat IgG), anti-PVRIG mAb, anti-PD-L1 mAb or anti-PVRIG + anti-PD-L1 mAb intraperitoneally (i.p.) starting on day 3 for six times (n = 8 per group). And median tumor size was shown. g, h C57BL/6 mice were inoculated subcutaneously (s.c.) with 2 × 10⁵ MC38 colon cancer cells. Mice were grouped randomly when tumor size reaches around 100–150 mm³ and treated with isotype-matched control mAb (Rat IgG) or anti-PVRIG mAb intraperitoneally (i.p.) for six times (n = 8 per group). g Median (left) and individual (right) tumor size was shown. h Overall survival of tumor-bearing mice was shown. Each symbol represents an individual mouse. Data were representative of at least two independent experiments. Error bars represent means ± s.e.m. Statistical significance was determined using two-way ANNOVA (b, f, g), Mantel–Cox test (c, h) or unpaired two-tailed t test (e). ns, p > 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001